Zydus’ manufacturing plant gets 5 U.S. FDA observations
The U.S. FDA issued five observations following an inspection of Zydus Lifesciences' manufacturing plant in Moraiya, Ahmedabad. The company stated it is working to address these findings promptly.
Why it matters
Regulatory observations from the FDA can impact a pharmaceutical company's production capabilities and international market access.
The U.S. Food and Drug Administration (U.S. FDA) has issued five observations, post inspection, to the manufacturing plant of Zydus in Moraiya, Ahmedabad.
The inspection was conducted from October 5-13 and closed with 5 observations. The company will closely work with the U.S. FDA to address the observations expeditiously, Zydus Lifesciences said on Tuesday.
Published - October 14, 2026 07:38 pm IST
pharmaceutical / medicine / business (general)
Terms & conditions | Institutional Subscriber
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in